Screener Summaries Updates Institutions Sign In More Updates › Other Events › AVTX Other Events · Jun 8, 2026
Avalo Therapeutics, Inc. held its 2026 annual meeting of stockholders, where stockholders approved the Second Amended… AVTX Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. held its 2026 annual meeting of stockholders, where stockholders approved the Second Amended and Restated 2016 Employee Stock Purchase Plan (A&R 2016 ESPP) and elected seven board nominees. Additionally, stockholders also ratified the following: Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year 2026.
More from Avalo Therapeutics, Inc. Avalo Therapeutics establishes $200M ATM equity program with Jefferies Nov 5, 2026 Avalo Therapeutics reports Q3 net loss of $18.9M and holds $462.8M in cash Nov 5, 2026 Avalo Therapeutics reported financial results for the quarter ended June 30, 2026, reporting a net loss of $36.4… Aug 6, 2026 Avalo Therapeutics, Inc. appointed Ron Philip to its Board of Directors, effective June 23, 2026 Jun 23, 2026 Avalo Therapeutics, Inc. announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal… Jun 16, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
